Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 16/20 | 0.69 |
| ▸ | AURKA | O14965 | 4/20 | 0.55 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.53 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL658077 | 1.00 | SYK (0.69) | SYKAURKAMAPK8AURKBCDK19 | |
| SCHEMBL655970 | 0.92 | SYK (0.69) | SYKAURKAMAPK8AURKBCDK19 | |
| SCHEMBL656341 | 0.92 | SYK (0.69) | SYKAURKAMAPK8AURKBCDK19 | |
| SCHEMBL653844 | 0.90 | SYK (0.57) | SYKAURKAMAPK8AURKB | |
| SCHEMBL2103711 | 0.86 | SYK (0.53) | SYKAURKAMAPK8AURKB | |
| SCHEMBL658235 | 0.86 | SYK (0.53) | SYKAURKAMAPK8AURKB | |
| SCHEMBL657177 | 0.84 | SYK (0.54) | SYKAURKAMAPK8AURKB | |
| SCHEMBL656270 | 0.84 | SYK (0.72) | SYKAURKA | |
| SCHEMBL2103984 | 0.83 | SYK (0.53) | SYKAURKAMAPK8AURKB | |
| SCHEMBL2103550 | 0.83 | SYK (0.50) | SYKAURKAMAPK8AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2130541-A2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | Rigel Pharmaceuticals, Inc. (US) | 2009-12-09 | — | — | EP | claimed |
| US-20080027034-A1 | Ciclesonide and Syk Inhibitor Combination and Method of Use Thereof | NYCOMED GMBH (DE) | 2008-01-31 | — | — | US | claimed |
| EP-1796679-A1 | CICLESONIDE AND SYK INHIBITOR COMBINATION AND METHODS OF USE THEREOF | Altana Pharma AG (DE) | 2007-06-20 | — | — | EP | claimed |
| EP-1791538-A1 | ROFLUMILAST AND SYK INHIBITOR COMBINATION AND METHODS OF USE THEREOF | Altana Pharma AG (DE) | 2007-06-06 | — | — | EP | claimed |
| WO-2006027378-A1 | ROFLUMILAST AND SYK INHIBITOR COMBINATION AND METHODS OF USE THEREOF | ALTANA PHARMA AG (DE) | 2006-03-16 | — | — | WO | claimed |
| US-20060058292-A1 | N4-[2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; inhibit the immunoglobulins IgE or IgG receptor signaling cascades in mast, basophil cells; antiallergen, antiinflammatory agent; asthma, osteoarthritis | MIDCAP FINANCIAL TRUST | 2006-03-16 | — | — | US | claimed |
| WO-2006027377-A1 | CICLESONIDE AND SYK INHIBITOR COMBINATION AND METHODS OF USE THEREOF | ALTANA PHARMA AG (DE) | 2006-03-16 | — | — | WO | claimed |
| US-20240158756-A1 | FEEDER-BASED AND FEEDER-FREE STEM CELL CULTURE SYSTEMS FOR STRATIFIED EPITHELIAL STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-05-16 | — | — | US | disclosed |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| WO-2021072238-A1 | FEEDER-BASED AND FEEDER-FREE STEM CELL CULTURE SYSTEMS FOR STRATIFIED EPITHELIAL STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2021-04-15 | — | — | WO | disclosed |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | Rigel Pharmceuticals, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-10709703-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10682350-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20060025410-A1 | N4-(1,4-Benzoxazin-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine or a salt, hydrate, solvate and/or N-oxide; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors | MIDCAP FINANCIAL TRUST | 2006-02-02 | — | — | US | disclosed |
| CN-1678321-A | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS INC (US) | 2005-10-05 | — | — | CN | disclosed |
| US-20050209230-A1 | 2-leaving group-4-(substituted amino)-5-fluoropyrimidines such as 2-chloro-N4-(2-hydroxyphenyl)-5-fluoro-4-pyrimidineamine; chemical intermediates to compounds that inhibit the immunoglobulin (Ig) IgE and/or IgG receptor signaling cascades | MIDCAP FINANCIAL TRUST | 2005-09-22 | — | — | US | disclosed |
| US-20050038243-A1 | Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents | MIDCAP FINANCIAL TRUST | 2005-02-17 | — | — | US | disclosed |
| EP-1471915-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040029902-A1 | Antiinflamamtory agents | MIDCAP FINANCIAL TRUST | 2004-02-12 | — | — | US | disclosed |
| WO-2003063794-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027034-A1 | Ciclesonide and Syk Inhibitor Combination and Method of Use Thereof | SYK, ZAP70, BTK | SYK 1/4885AURKA 1484/4885MAPK8 3396/4885 |
| US-20060058292-A1 | N4-[2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; inhibit the immunoglobulins IgE or IgG receptor signaling cascades in mast, basophil cells; antiallergen, antiinflammatory agent; asthma, osteoarthritis | FCER2, FCGR1A, HRH4 | SYK 36/4885AURKA 533/4885MAPK8 1076/4885 |
| US-20040029902-A1 | Antiinflamamtory agents | FCER2, FCGR1A, HNMT | SYK 251/4885AURKA 1221/4885MAPK8 1522/4885 |
| US-10682350-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | SYK 54/4885AURKA 997/4885MAPK8 746/4885 |
| US-10709703-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | SYK 54/4885AURKA 997/4885MAPK8 746/4885 |
| US-20060025410-A1 | N4-(1,4-Benzoxazin-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine or a salt, hydrate, solvate and/or N-oxide; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors | SYK, FCER2, FCGR1A | SYK 1/4885AURKA 288/4885MAPK8 725/4885 |
| US-20050209230-A1 | 2-leaving group-4-(substituted amino)-5-fluoropyrimidines such as 2-chloro-N4-(2-hydroxyphenyl)-5-fluoro-4-pyrimidineamine; chemical intermediates to compounds that inhibit the immunoglobulin (Ig) IgE and/or IgG receptor signaling cascades | FCER2, FCGR1A, FCGR2A | SYK 42/4885AURKA 1583/4885MAPK8 1172/4885 |
| US-20050038243-A1 | Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents | FCER2, FCGR1A, FCGR2A | SYK 83/4885AURKA 3432/4885MAPK8 558/4885 |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | SYK 54/4885AURKA 997/4885MAPK8 746/4885 |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | SYK 54/4885AURKA 997/4885MAPK8 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.